Gilda G Hillman Selected Research

Isoflavones

1/2020	Isoflavone-mediated radioprotection involves regulation of early endothelial cell death and inflammatory signaling in Radiation-Induced lung injury.
1/2019	Soy Isoflavones Protect Normal Tissues While Enhancing Radiation Responses.
9/2017	Radiation injury to cardiac arteries and myocardium is reduced by soy isoflavones.
1/2017	Innate Immune Pathways Associated with Lung Radioprotection by Soy Isoflavones.
12/2015	Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of Radiation-Induced Activation of Macrophages and Neutrophils.
1/2015	Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones.
11/2013	Radioprotection of lung tissue by soy isoflavones.
10/2013	Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma.
1/2012	DNA Repair and Cancer Therapy: Targeting APE1/Ref-1 Using Dietary Agents.
11/2011	Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gilda G Hillman Research Topics

Disease

32	Neoplasms (Cancer) 01/2019 - 01/2003
14	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 10/2004
10	Fibrosis (Cirrhosis) 09/2017 - 08/2003
8	Lung Neoplasms (Lung Cancer) 01/2020 - 11/2011
8	Neoplasm Metastasis (Metastasis) 07/2011 - 01/2003
7	Pneumonia (Pneumonitis) 01/2020 - 10/2013
7	Carcinoma (Carcinomatosis) 05/2014 - 01/2003
6	Inflammation (Inflammations) 01/2020 - 11/2011
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2004
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 04/2011
4	Radiation Injuries (Radiation Sickness) 09/2017 - 11/2011
3	Lung Injury 01/2020 - 12/2015
3	Lymphatic Metastasis 06/2007 - 07/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 09/2017
2	Residual Neoplasm 05/2014 - 11/2011
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 09/2017
1	Heart Failure 09/2017
1	Ischemia 09/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 09/2017
1	Myocardial Infarction 09/2017
1	Esophagitis 01/2015
1	Hypertrophy 01/2015
1	Hypertension (High Blood Pressure) 10/2014
1	Fatigue 10/2014
1	Glioma (Gliomas) 10/2014
1	Weight Loss (Weight Reduction) 05/2014
1	Vascular System Injuries 05/2014
1	Alopecia (Baldness) 11/2013
1	Hemorrhage 11/2011
1	Hypoxia (Hypoxemia) 06/2007
1	Necrosis 10/2004

Drug/Important Bio-Agent (IBA)

21	IsoflavonesIBA 01/2020 - 04/2006
7	GenisteinIBA 06/2010 - 10/2004
6	Proteins (Proteins, Gene)FDA Link 03/2007 - 10/2003
3	AntioxidantsIBA 01/2019 - 12/2007
3	Biological ProductsIBA 01/2019 - 07/2011
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2017 - 05/2003
3	Pharmaceutical PreparationsIBA 05/2014 - 04/2004
3	NF-kappa B (NF-kB)IBA 04/2009 - 04/2006
3	Histocompatibility Antigens Class IIIBA 06/2004 - 04/2004
2	VaccinesIBA 01/2017 - 06/2004
2	Cancer VaccinesIBA 01/2017 - 05/2003
2	Sunitinib (Sutent)FDA Link 10/2014 - 09/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2014 - 04/2009
2	Hormones (Hormone)IBA 05/2012 - 06/2010
2	Transcription Factors (Transcription Factor)IBA 07/2011 - 04/2009
2	glyciteinIBA 06/2010 - 03/2007
2	daidzeinIBA 06/2010 - 03/2007
2	Peptides (Polypeptides)IBA 06/2004 - 05/2004
2	Histocompatibility Antigens Class IIBA 06/2004 - 05/2004
2	EpitopesIBA 05/2004 - 04/2004
2	AntigensIBA 05/2004 - 04/2004
2	CytokinesIBA 01/2004 - 08/2003
2	Interleukin-2 (IL2)IBA 10/2003 - 08/2003
1	Complement System Proteins (Complement)IBA 09/2017
1	TG4010IBA 01/2017
1	CollagenIBA 01/2015
1	Transaminases (Aminotransferases)IBA 10/2014
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2014
1	Axitinib (AG 013736)IBA 05/2014
1	Angiogenesis InhibitorsIBA 05/2014
1	Androgen Receptors (Androgen Receptor)IBA 05/2012
1	TabletsIBA 11/2011
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 07/2011
1	Antineoplastic Agents (Antineoplastics)IBA 07/2011
1	EnzymesIBA 07/2011
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 07/2011
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 09/2009
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 09/2009
1	PhytochemicalsIBA 12/2007
1	Therapeutic UsesIBA 06/2007
1	EndonucleasesIBA 03/2007
1	Cyclin B1IBA 04/2006
1	invariant chain (Ii-Key)IBA 02/2005
1	HLA-DR Antigens (HLA-DR)IBA 05/2004
1	MHC class II transactivator proteinIBA 10/2003
1	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2003
1	AcidsIBA 01/2003
1	Arachidonate 12-Lipoxygenase (12 Lipoxygenase)IBA 01/2003
1	LipidsIBA 01/2003
1	Arachidonic Acid (Vitamin F)IBA 01/2003

Therapy/Procedure

25	Radiotherapy 01/2020 - 05/2003
9	Therapeutics 01/2017 - 08/2003
3	Injections 01/2017 - 05/2003
3	Immunotherapy 06/2004 - 10/2003
2	Chemoprevention 01/2012 - 12/2007
2	Drug Therapy (Chemotherapy) 01/2012 - 09/2009